Immunologic Response of HIV-Infected Children to Different Regimens of Antiretroviral Therapy: A Retrospective Observational Study

Table 1

Comparative baseline characteristics of the cohort at JMC, from April 10 to May 10, 2017.

All n = 179		ABC group (n = 87)	AZT group (n = 92)	value
Variables
Sex	Male	42 (48.3%)	39 (42.4%)	0.42
	Female	45 (51.7%)	53 (57.6%)
Age (years)	<3 years	11 (12.6%)	12 (13.0%)	0.97
	3–5 years	18 (20.7%)	20 (21.7%)
	>5 years	58 (66.7%)	60 (65.2%)
BMI (baseline)	<5^th centile	74 (85.0%)	66 (71.7%)	0.03
	>5^th centile	13 (14.9%)	26 (28.3%)
Maternal HIV status	Positive	78 (89.7%)	83 (90.2%)	0.91
	Unknown	9 (10.3%)	9 (9.8%)
Area of residence	Urban	66 (75.9%)	68 (73.9%)	0.76
	Rural	21 (24.1%)	24 (26.1%)
Baseline CD4+ (mean +SD)	166.31 + 76.223	178.78 + 71.12	0.26
WHO stage	I	8 (9.2%)	3 (3.3%)	0.08
	II	24 (27.6%)	40 (43.5%)
	III	45 (51.7%)	42 (45.7%)
	IV	10 (11.5%)	7 (7.6%)
Functional status	W/A	72 (82.8%)	88 (95.7%)	0.001
	A/D	12 (13.8%)	0
	B/r	3 (3.4%)	4 (4.3%)
TB (treatment)	Yes	3 (3.4%)	9 (9.8%)	0.06
	No	84 (96.6%)	83 (90.2%)
OI prophylaxis	Both CPT and INH	85 (97.7%)	89 (96.7%)	0.69
	CPT only	1 (1.1%)	1 (1.1%)
	Neither	1 (1.1%)	2 (2.2%)
Nutritional status	Normal	45 (51.7%)	57 (62.0%)	0.17
	SAM	42 (48.3%)	35 (38.0%)